Compare · ERAS vs NVO
ERAS vs NVO
Side-by-side comparison of Erasca Inc. (ERAS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ERAS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 33.4x ERAS ($5.20B).
- Over the past year, ERAS is up 455.8% and NVO is down 28.6% - ERAS leads by 484.4 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for ERAS).
- NVO has more recent analyst coverage (25 ratings vs 19 for ERAS).
- Company
- Erasca Inc.
- Novo Nordisk A/S
- Price
- $13.39-9.95%
- $38.82-1.05%
- Market cap
- $5.20B
- $173.66B
- 1M return
- -12.74%
- -10.14%
- 1Y return
- +455.81%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 4
- Recent ratings
- 19
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ERAS
- SEC Form 8-K filed by Erasca Inc.
- Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
- Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Erasca Inc. filed SEC Form 8-K: Other Events
- Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
- SEC Form 144 filed by Erasca Inc.
- SEC Form 4 filed by President, R&D Fuchs Charles S.
- SEC Form 3 filed by new insider Fuchs Charles S.
- SEC Form S-8 filed by Erasca Inc.
- SEC Form 10-Q filed by Erasca Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank